

WELCOME

Moin!

On behalf of the Scientific Committee, we are pleased to invite you to the 1st Joint Educational Meeting of the Chronic Malignancies Working Party (CMWP) and the Cellular Therapy and Immunobiology Working Party (CTIWP) of the EBMT, to be held in Hamburg, Germany, on 24th to 26th November 2023. This event will present the most recent advances and new perspectives in the field of immunology and cellular therapy for multiple myeloma and plasma disorders, including current practical challenges and new patient-centered perspectives.

The plenary conference programme is designed to place emphasis on leading-edge basic and clinical research. This shall be a platform for deliberate interaction, sharing of experiences and active and open scientific discourse and debate. Everything will be embedded in the Beauty of Germany's north, Hamburg, with a dedicated and warm environment for active networking.

Annalisa Ruggeri, CTIWP Chair
Donal McLornan, CMWP Chair
Nico Gagelmann, local organiser

Friday, 24 November 2023

Plenary Room

10:00 - 13:00	Chronic Malignancies Working Party Scientific Business Meeting Open for everybody
13:00 - 14:00	Lunch Break
14:00 - 16:00	Chronic Malignancies Working Party Scientific Business Meeting Open for everybody
16:00 - 16:15	Coffee Break
16:15 - 17:15	Joint Meeting
17:15 - 18:00	Keynote Lecture Placement of cellular therapies in treatment algorithm of PCDs Carlos Fernández de Larrea (ES)

Breakout Room

10:30 - 13:00	Cellular Therapy and Immunobiology Working Party Scientific Business Meeting Open for everybody
13:00 - 14:00	Lunch Break
14:00 - 16:00	Cellular Therapy and Immunobiology Working Party Scientific Business Meeting Open for everybody
16:00 - 16:15	Coffee Break
16:15 - 17:15	Joint Meeting at Plenary Room

Saturday, 25 November 2023

Plenary Room

09:00 – 10:00

Session I: Basics of myeloma

Chair: Meral Beksac (TR)

09:00-09:15
09:15-09:30
09:30-09:45
09:45-10:00

Diagnostic and treatment algorithm in MM
Diagnostic and treatment algorithm in amyloidosis
Diagnostic and treatment algorithm in WM, MGCS, MGRS
Q&A

Patrick Hayden (IE)
Monique Minnema (NL)
Shirley D'Sa (UK)

10:00 – 11:00

Session II: Preclinical models in MM

Chair: Florent Malard (FR)

10:00-10:15
10:15-10:30
10:30-10:45
10:45-11:00

Genomic evolution
Omics
Microbiome
Q&A

Niels Weinhold (DE)
Marc Raab (DE)
Florent Malard (FR)

11:00 – 11:30

Coffee Break

11:30 – 12:35

Session III: Immune microenvironment in disease

Chairs: Joanna Drozd-Sokolowska (PL) – Kavita Raj (UK)

11:30-11:45
11:45-12:00
12:00-12:15
12:15-12:20
12:20-12:35

T-cells
NK cells
Mechanisms of EMD
Case presentation: Refractory Multiple Myeloma with
Challenging Extramedullary Disease
Q&A

Kim de Veirman (NL)
Michael O'Dwyer (IE)
Tomáš Jelinek (CZ)

Esra Gülderen (TR)

12:35 - 13:30

Session IV: Novel cellular therapies

Chair: Lydia Lee (UK)

12:35-12:45
12:45-12:55
12:55-13:05
13:05-13:15
13:15-13:30

Novel targets
NK cells, macrophages, fibroblasts
Harvesting the therapeutic potential of gdT
cells for cancer immune therapies
Immune signalling at the tumour: bone marrow niche in
multiple myeloma: a view to a kill
Q&A

Luis G. Rodríguez-Lobato (ES)
Niels Weinhold (DE)

Jürgen Kuball (NL)

Graeme Sullivan (IE)

13:30 - 14:30

Lunch Break

14:30 – 15:15

Session V: Procedural aspects

Chair: Stefan Schönland (DE)

14:30-14:45

Cell collection and manufacturing

Christian Chabannon (FR)

14:45-15:00

AI

Alexander Oeser (DE)

15:00-15:15

Q&A

15:15 – 16:00

Session VI: New and "old" kids on the block

Chair: Gösta Gahrton (SE)

15:15-15:30

Finding the optimal drug combination for rrMM

Fredrik Schjesvold (NO)

15:30-15:45

Role of autograft

Mauricette Michallet (FR)

15:45-16:00

Q&A

16:00 – 16:30

Coffee Break

16:30 – 17:30

Session VII: Current state of CAR-T in PCD

Chair: Nico Gagelmann (DE)

16:30-16:45

Ide-cel and cilta-cel: trial insights

Yael Cohen (IL)

16:45-17:00

Real-world and GOCART

Nico Gagelmann (DE)

17:00-17:15

Academic

Lydia Lee (UK)

17:15-17:30

Q&A

17:30 – 18:15

Keynote lecture

Chair: Anna Sureda (ES)

Lessons and new insights in allogeneic CAR-T and transplant

Nicolaus Kröger (DE)

Saturday, 25 November 2023

*Breakout Room
Nurses' track*

09:10 – 09:15	Welcome	
09:15 – 10:15	Session I: Multiple myeloma, the basics, and new treatment options	
09:15–10:15	Multiple myeloma (the basics), new treatment options, and what's important in the patients screening for CART cell therapy in the MM field (frail/unfit screening)	Laurent Garderet (FR)
10:15 – 11:00	Session II (part I): Toxicity during CART cell therapy and bispecific	
10:15–11:00	CAR-T	Maaïke de Ruijter (NL)
11:00 – 11:30	Coffee Break	
11:30 – 12:15	Session II (part II): Toxicity during CART cell therapy and bispecific	
11:30–12:15	Bispecifics	Marianne Elshoud (NL)
12:15 – 13:15	Session III: The role of the research nurse and nurse specialist in the patient Pathway (CART and bispecific)	
12:15–12:45	CAR-T	Sandy Kruyswijk (NL)
12:45–13:15	Bispecifics	Maaïke de Ruijter (NL)
13:15 – 13:30	Closing Remarks	
13:30 – 14:30	Lunch Break	

Sunday, 26 November 2023

Plenary Room

09:00- 10:00

Session VIII: Biology of response and relapse

Chair: Annalisa Ruggeri (IT)

09:00-09:15

High-risk Myeloma transplant vs CART

Christoph Schaefers (DE)

09:15-09:30

Antigen loss and microenvironment

Sarah Gooding (UK)

09:30-09:45

Immune monitoring

Christof Scheid (DE)

09:45-10:00

Q&A

10:00 - 10:55

Industry Symposium on “Novel therapies in multiple myeloma”

Kindly sponsored by Janssen

Chair: Hermann Einsele (DE)

10:00-10:10

Novel immune and cellular therapies

Hermann Einsele (DE)

10:10-10:25

CAR T cells - patient selection and treatment of toxicities

Christof Scheid (DE)

10:25-10:40

Management of infections & mitigations strategies

Cyrus Khandanpour (DE)

10:40-10:55

Q&A

10:55 – 11:25

Coffee Break

11:25 – 12:25

Session IX: Monitoring and treating resistance

Chair: Yael Cohen (IL)

11:25-11:40

Multi-targeting

Mohamad Mohty (FR)

11:40-11:55

Role of MRD

Noemi Puig (ES)

11:55-12:10

Bispecifics

Hermann Einsele (DE)

12:10-12:25

Q&A

12:25 – 13:25

Session X: Patient fitness and toxicities

Chair: Donal McLornan (UK)

12:25-12:40

Is there "eligibility" for CAR-T?

Laurent Garderet (FR)

12:40-12:55

Mechanisms and strategies for neurotoxicity

Ibrahim Yakoub-Agha (FR)

12:55-13:10

Hematotoxicity and others

Meral Beksac (TR)

13:10-13:25

Q&A

13:25 – 13:40

Closing Remarks

Donal McLornan (UK)

Annalisa Ruggeri (IT)

THANKS TO OUR SPONSORS

Industry Symposium Partner



Gold Partner



Silver Partners



Bronze Partners

